Notably, the Her2-positive breast cancer subtype in TCGA had threefold more APOBEC-driven SGMs than all other subtypes combined (2.9 versus 0.95 SGMs per genome) (Fig. 4B), consistent with earlier studies showing higher APOBEC activity in that subtype (8). This evidence concerns the gene ERBB2 and breast carcinoma.